BioXcel Therapeutics (BTAI) Change in Cash (2017 - 2026)

BioXcel Therapeutics has reported Change in Cash for 10 years, with the latest figure at -$3.4 million in Q2 2026.

• On a quarterly basis, Change in Cash rose 72.83% year-over-year to -$3.4 million in Q2 2026; TTM through Jun 2026 was -$4.8 million, a 87.34% increase from a year earlier, with the FY2025 full-year figure at -$1.1 million, up 96.9% from the prior year.
• Change in Cash was -$3.4 million for Q2 2026 at BioXcel Therapeutics, up from -$11.6 million in the prior quarter.
• The five-year high for Change in Cash was $33.0 million in Q2 2022, with the low at -$38.6 million in Q4 2022.
• Average Change in Cash over 5 years is -$12.2 million, with a median of -$12.0 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Change in Cash plunged 3202.64% in 2023, then soared 218.01% in 2025.
• Over 5 years, Change in Cash stood at -$38.6 million in 2022, then soared by 35.89% to -$24.7 million in 2023, then surged by 57.43% to -$10.5 million in 2024, then grew by 18.7% to -$8.6 million in 2025, then soared by 60.54% to -$3.4 million in 2026.
• The last three Change in Cash figures came in at -$3.4 million (Q2 2026), -$11.6 million (Q1 2026), and -$8.6 million (Q4 2025), per Business Quant data.